^
Association details:
| Biomarker: | BTK C481S |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Calquence (acalabrutinib) (BTK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Acalabrutinib is not effective for ibrutinib-refractory CLL with BTK C481S mutations.
